If I had to chose one stock to own this next year you are looking at it. Long since 1.90's. Chart is setting up perfectly for 3/22 Data readout. Broke resistance today. Held up beautifully in market downturn. If this completes a phase 2 trial for Factor D I will be shocked. Strong buyout candidate for rare disease field.